Abstract

a virological response (undetectable [<600 IU/ml.] or a 2dog0 drop in HO/RNA serum concentrations) treatment week 4 The most frequently reported adverse events included headache myalgia, py~'exia, tatigue and anorexia: most were mild or moderate in intensity. No signs of opioid withdrawal were observed No patient modified methadone or PEG-IFN doses during the sudy One subject withdrew prematurely due to poor venous access. Conclusions: PEGqFN monotberapy is well-tolerated by CHC patients receiving MMT. PEGIFN and methadone do not significantly alter the PK of each respective therapy. Biologic response as assessed 2,5 -OAS activity was similar to that in healthy subjects. HCV RNA dechne was similar to that seen in CHC patients not receiving MMT These data suggest that MMT does not impair the antiviral activ W of PEG-IFN

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.